Previously, galectin-1 (GAL1) was found to be up-regulated in obesity-prone subjects, suggesting that use of a GAL1 inhibitor could be a novel therapeutic approach for treatment of obesity. This evidence concerns the gene LGALS1 and obesity due to melanocortin 4 receptor deficiency.